Selected article for: "cell epitope and present cell epitope"
Author: Christine Dahlke; Jasmin Heidepriem; Robin Kobbe; Rene Santer; Till Koch; Anahita Fathi; My L. Ly; Stefan Schmiedel; Peter H. Seeberger; Marylyn M. Addo; Felix F. Loeffler
Title: Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series
  • Document date: 2020_4_17
    • ID: icl1t9d6_41
    Snippet: Collectively, while antibody dynamics and B-cell epitopes were studied previously, we present the first longitudinal sample analysis of individual B-cell epitope development at early disease phases, comparing degree of disease severity. These data can be the starting point for the development of vaccines or therapeutic antibodies. All rights reserved. No reuse allowed without permission......
    Document: Collectively, while antibody dynamics and B-cell epitopes were studied previously, we present the first longitudinal sample analysis of individual B-cell epitope development at early disease phases, comparing degree of disease severity. These data can be the starting point for the development of vaccines or therapeutic antibodies. All rights reserved. No reuse allowed without permission.

    Search related documents:
    Co phrase search for related documents
    • antibody dynamic and disease severity: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • antibody dynamic and early disease phase: 1
    • antibody dynamic and therapeutic antibody: 1
    • disease phase and early disease phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease phase and previously study: 1, 2, 3, 4
    • disease phase and starting point: 1, 2, 3
    • disease severity and early disease phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • disease severity and previously study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • disease severity and sample analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • disease severity and starting point: 1, 2, 3
    • disease severity and therapeutic antibody: 1, 2, 3, 4, 5, 6
    • early disease phase and previously study: 1, 2
    • previously study and sample analysis: 1